First patient dosed in canbridge pharmaceuticals can103 phase 2 trial for the treatment of gaucher disease in china

Beijing & burlington, mass.--( business wire )--canbridge pharmaceuticals, inc. (1228.hk), a global biopharmaceutical company, with a foundation in china, committed to the research, development and commercialization of transformative therapies to treat rare diseases and oncology, announced that the first patient has been dosed in the phase 2 part of the ongoing can103 phase 1/2 trial in treatment-naÏve patients with gaucher disease (gd) types i and iii in china. bing han md, phd, chief physician and professor in the department of hematology at peking union medical college hospital in beijing, china, is the principal investigator for this multi-site trial.
GD Ratings Summary
GD Quant Ranking